Informed Prostate Cancer Patient Support

Prostate Cancer: Forms, Symptoms, and Treatment babyboomers.com Prostate Cancer: Forms, Symptoms, and Treatment 5–7 minutes The prostate is an important part of the male reproductive system which is responsible for the production of seminal fluid, a fluid nutrient medium, and the transport in which sperm are suspended. The prostate is located just below the bladder, where it regulates urination. Prostate cancer, also known as prostate carcinoma or prostate neoplasm, describes a disease in which cells in the prostate gland begin to multiply uncontrollably or without normal cell regulation, causing a tumor. The American Cancer Society speculates 268,490 new cases and approximately 34,500 deaths from prostate cancer in the United States for 2022 and suggests that the risk of prostate cancer is approximately 1 in 8 men over a man's lifetime. Prosta

Promising prostate cancer drug hints at improved immunotherapy

Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey−Holden prostate cancer academy meeting - Miyahira - The Prostate - Wiley Online Library

Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer | Prostate Cancer and Prostatic Diseases

Metastasis-Directed Therapy May Delay ADT in Advanced Prostate Cancer | MedPage Today : Surgery or radiation delayed initiation of systemic therapy by 18 months

Enzyme reverses muscle loss due to cancer and aging

Drug Identified by WUSL Researchers Triggers Immune Cells to Attack Prostate Cancer

Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine | Prostate Cancer and Prostatic Diseases

Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy | Prostate Cancer and Prostatic Diseases

What Public Health Messaging Gets Wrong About Prostate Cancer

Drug triggers immune cells to attack prostate cancer: Compound kills tumors in mice, human cancer cells in multiple ways -- ScienceDaily

Late toxicity of moderately hypofractionated intensity-modulated proton therapy treating the prostate and pelvic lymph nodes for high-risk prostate cancer - International Journal of Radiation Oncology, Biology, Physics Abstract Purpose To evaluate late gastrointestinal (GI) and genitourinary (GU) toxicity of moderately hypofractionated intensity-modulated proton therapy (IMPT) targeting the prostate and pelvic lymph nodes. Methods and Materials A target accrual of 56 patients with high-risk or unfavorable intermediate risk prostate cancer were enrolled into a prospective study (ClinicalTrials.gov: XXX) of moderately hypofractionated IMPT. IMPT with pencil beam scanning was utilized to deliver 6750 and 4500 cGy RBE in 25 daily fractions simultaneously to the prostate and pelvic lymph nodes, respectively. All received androgen deprivation therapy. Late GI and GU toxicity was prospectively asses

Using Attention-based Deep Learning to Predict ERG:TMPRSS2 Fusion Status in Prostate Cancer from Whole Slide Images | bioRxiv : Prostate cancer (PCa) is associated with several genetic alterations which play an important role in the disease heterogeneity and clinical outcome including gene fusion between TMPRSS2 and members of the ETS family of transcription factors specially ERG. The expanding wealth of pathology whole slide images (WSIs) and the increasing adoption of deep learning (DL) approaches offer a unique opportunity for pathologists to streamline the detection of ERG:TMPRSS2 fusion status. Here, we used two large cohorts of digitized H&E-stained slides from radical prostatectomy specimens to train and evaluate a DL system capable of detecting the ERG fusion status and also detecting tissue regions of high diagnostic and prognostic relevance. Slides from the PCa TCGA dataset were split into training (n=318), validation (n=59), and testing sets (n=59) with the training and

Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations | Prostate Cancer and Prostatic Diseases

Moving AS to the next level: Can we help more patients? - YouTube : The Active Surveillance Coalition, a collaboration of leading Active Surveillance support groups for prostate cancer is sponsoring a webinar that could prov...

Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer | Prostate Cancer and Prostatic Diseases

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer - Su - The Prostate - Wiley Online Library : Background PARP (poly(ADP-ribose) polymerase) inhibitors (PARPi) are now standard of care in metastatic castrate-resistant prostate cancer (mCRPC) patients with select mutations in DNA damage repair...

Tumor Board Reviewing the Use of PSMA PET in Prostate Cancer, Gleason 4+4=8 GG 4 - Session 2 Case 6 - H Jacene, A Kibel, P Nguyen, & A Morgans : case based discussion of patient with past medical history of high risk localized prostate cancer, Gleason 4+4 grade group four prostate cancer, repeat MRI of the prostate, PSMA PET CT scan, intense PSMA uptake correlating to that right operator lymph node confirming metastatic disease

Targeting refractory prostate cancer: A novel radiopharmaceutical hits the bull's eye: Radiopharmaceutical treatment targeting prostate-specific membrane antigen effectively shrinks prostate tumors in mice -- ScienceDaily : Researchers have found a new theranostic compound that effectively shrinks prostate tumor in mice. Theranostics is a cancer treatment that involves finding cancer cells anywhere in the body and delivering targeted radiation to kill those cells, by drugs that contain radioactive isotopes. It means that this compound could be a promising option for treating hormone-resistant metastases in patients with recurrent cancers.

A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer | bioRxiv

Germline determinants of the prostate tumor genome | bioRxiv

ESSA Pharma: Combination Shows Efficacy In Prostate Cancer (TSXV:EPI:CA) | Seeking Alpha

Comparison of machine learning to deep learning for automated annotation of Gleason patterns in whole mount prostate cancer histology. | bioRxiv

FLASH radiotherapy cancer treatment aces first human trial

PSMA PET- and mpMRI-directed Prostate Cancer Salvage - ScienceDirect We congratulate Raman et al on their analysis of patients who received restaging 18F-DCFPyL positron emission spectroscopy (PET) for biochemical recurrence (BR) after primary brachytherapy. 1 Seventy of 73 patients (96%) who received PET for BR after low-dose-rate (LDR) monotherapy had a true positive PET, and 38 of 70 patients (54%) had isolated local recurrence. Furthermore, most intraprostatic recurrences (69%) were in the same sextant as the original diagnostic biopsy results. These findings suggest a potential role for local salvage therapies.  

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): A Multicenter, Randomized Phase II Trial - ScienceDirect Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): A Multicenter, Randomized Phase II Trial Author links open overlay panel C. Tang 1 A.D. Sherry 2 C. Haymaker 2 T. Bathala 2 S. Liu 3 B. Fellman 3 A. Aparicio 4 A. Zurita-Saavedra 5 S.. Chun 6 J. Reddy 1 E. Efstathiou 2 J. Wang 2 P. Pilie 2 A. Reuben 2 C. Kovitz 2 R. Kumar 7 B. Chapin 8 D.R. Gomez 9 … P.G. Corn 11 https://doi.org/10.1016/j.ijrobp.2022.09.006 Get rights and content Purpose/Objective(s) There has been increased utilization of metastasis directed therapy (MDT) for oligometastatic prostate cancer. Despite data demonstrating the benefit of upfront hormone therapy (HT) and synergy between radiation and HT, there exists no randomized trials testing their combination. As it is accep

Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 4+4=8 GG 4, Past Medical History of High Risk Localized Prostate Cancer - Session 2 Case 6 - H Jacene, A Kibel, P Nguyen, & A Morgans

Tumor Board Reviewing the Use of PSMA PET in the Care of Patient with Gleason 3+3=6 GG 1 Prostate Adenocarcinoma and PALB2 Mutation - Session 2 Case 3 H Jacene, A Kibel, P Nguyen, & A Morgans : prostate cancer tumor board Gleason 3+3=6 Grade Group 1 prostate adenocarcinoma, prostate cancer tumor board PALB2 mutation prostate cancer patient, MRI of the prostate PI-RADS 5 lesion multiple enlarged pelvic lymph nodes prostate cancer case review, H Jacene, A Kibel, P Nguyen, & A Morgans

A Fork in the Road on My 'Cancer Journey' | MedPage Today

Effect of positive surgical margins at radical prostatectomy on cancer‐specific mortality in high/very high‐risk prostate cancer patients with Gleason Grade Group 4–5 - Panunzio - The Prostate - Wiley Online Library : Background The effect of positive surgical margins (PSM) on cancer specific mortality (CSM) in high/very high-risk (HR/VHR) prostate cancer (PCa) with aggressive Gleason Grade Group (GGG) is unknown...

Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer | bioRxiv

Spatial regulation of the glycocalyx component Podocalyxin is a switch for pro-metastatic function | bioRxiv

Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis | Scientific Reports

Adipose triglyceride lipase is regulated by CAMKK2-AMPK signaling and drives advanced prostate cancer | bioRxiv : Lipid metabolism plays a central role in prostate cancer. To date, the major focus on prostate cancer lipid metabolism has centered on de novo lipogenesis and lipid uptake with little consideration for how cancer cells access these lipids once they are created or taken up and stored. Patient-derived phosphoproteomics identified adipose triglyceride lipase (ATGL), a previously suspected tumor suppressor, as a CAMKK2-AMPK signaling target that, conversely, promotes castration-resistant prostate cancer (CRPC) progression. Phosphorylation of ATGL increased its lipase activity, cancer cell proliferation, migration, and invasion. Shotgun lipidomics and mass spectrometry imaging demonstrated ATGL′s profound regulation of lipid metabolism in vitro and in vivo, remodeling membrane composition. Inhibition of ATGL induced metabolic plasticity, causing a glycolytic shift that could be

Ejaculation frequency and prostate cancer - Harvard Health health.harvard.edu Ejaculation frequency and prostate cancer - Harvard Health Despite the importance of prostate cancer , its causes remain unknown. Scientists do know that genetics plays a strong role, and they have sound evidence that diet and other lifestyle factors are also important. Since the prostate is a reproductive organ that produces fluid for the ejaculate, researchers have long wondered if sexual factors influence a man's risk of prostate cancer, but a Harvard study provides good news for sexually active men. The Harvard ejaculation study The Health Professionals Follow-Up Study has been collecting information about a large group of volunteers since 1986. All the men are health care providers, including dentists, pharmacists, veterinarians, optometrists, ophthalmologists, and podiatrists. Most are white. In 1992, 29,342 men bet

Developing therapies for treatment-resistant prostate cancer -- ScienceDaily sciencedaily.com Developing therapies for treatment-resistant prostate cancer 4-5 minutes Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal Molecular Therapy, have led to a larger, multicenter trial that will soon be underway. Cancer of the prostate, a small gland just below the bladder, is the second-leading cause of cancer-related death in men. Many prostate tumors are not aggressive and may require no or minimal treatment. Aggressive tumors are initially treated with surgery or radiation therapy. In about one-third of patients, the cancer comes back after initial treatment, said Neil Bhowmick, PhD, research scienti

Mental Distress: Prostate Cancer's 'Elephant in the Room'

Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study - Oishi - The Prostate - Wiley Online Library

The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis‐free survival in patients with relapsed prostate cancer following prostatectomy - Lee - The Prostate - Wiley Online Library

Temporary Reactive Response of Axillary Lymph Nodes to COVID-19 Vaccination on 18F-rhPSMA-7.3 PET/CT in Patients with Prostate Cancer | Journal of Nuclear Medicine

Oligometastatic Prostate Cancer: Current Status and Future Challenges | Journal of Nuclear Medicine

Robot-Assisted Prostate-Specific Membrane Antigen–Radioguided Surgery in Primary Diagnosed Prostate Cancer | Journal of Nuclear Medicine

Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic | Journal of Nuclear Medicine

Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study | Journal of Nuclear Medicine

The PRIMARY Score: Using Intraprostatic 68Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis | Journal of Nuclear Medicine

Programmed death-ligand 1 expression in human cancer three-dimensional cell culture models | bioRxiv

Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug | Journal of Nuclear Medicine